Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chronic Anticoagulation in End-stage Renal Disease Patients: Pharmacokinetics and Pharmacodynamic of a Reduced Dose Regimen of Rivaroxaban

NCT05410275 is registered in ClinicalTrials.gov with University Hospital, Tours as lead sponsor.

NCT NCT05410275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05410275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chronic Anticoagulation in End-stage Renal Disease Patients: Pharmacokinetics and Pharmacodynamic of a Reduced Dose Regimen of Rivaroxaban
Lead sponsor
University Hospital, Tours
Phase
Phase 3
Overall status
Recruiting
Start date
January 8, 2025
Completion date
January 30, 2027
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hemodialysis patients